Michael L. Linenberger
M.D., University of Kansas, 1982.
B.S., University of Kansas, 1978.
Current research interests include studies of mechanisms of drug resistance in acute myeloid leukemia (AML), including drug transporter mechanisms active against antibody-directed therapy. Other interests include optimization of methods for stem cell procurement, therapeutic apheresis approaches for post-transplant graft-versus-host disease, and cellular therapy applications relevant to hematopoietic stem cell transplantation.
Marrow and peripheral blood tem cell procurement;
AML treatment with antibody-based agents;
Iron overload disorders;
Benign and malignant hematologic disorders.
Prior Research Activity:
Mechanisms of retroviral-mediated hematopoietic suppression and leukemogenesis.
We are working to apply our knowledge of drug resistance mechanisms against antibody-based therapies for AML toward conducting clinical trials using drug resistance modulating agents.
We are working to develop clinical protocols to study the mechanisms and therapeutic efficacy of extracorporeal photochemotherapy for graft-versus-host disease.
Alpha Chi Sigma
Alpha Omega Alpha
American Association of Blood Banks
American College of Physicians
American Society for Apheresis
American Society of Hematology
International Society for Cellular Therapy
1993-2000, Assistant Professor, University of Washington, School of Medicine, Medicine, Hematology
1989-1993 University of Washington, Hematology, Acting Instructor
A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(1):8-17.. 2016.
NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology-oncology.. Journal of clinical apheresis. 31(1):38-47.. 2016.
Defining the quality of hematopoietic stem cell products: the devil is in the details.. Transfusion. 55(10):2300-3.. 2015.
Therapeutic apheresis for patients with cancer.. Cancer control : journal of the Moffitt Cancer Center. 22(1):60-78.. 2015.
Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9.. Blood. 126(25):2734-2738.. 2015.
Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014.
American Society for Apheresis Guidelines Support Use of Red Cell Exchange Transfusion for Severe Malaria With High Parasitemia.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2013.
Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.. Journal of clinical apheresis. 28(3):145-284.. 2013.
Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic Engraftment.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(2):220-228.. 2012.
Chasing clot: thrombophilic states and the interventionalist.. Journal of vascular and interventional radiology : JVIR. 20(11):1403-16;quiz1417.. 2009.
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 6(8):716-53.. 2008.